0      0

24th Napa Pain Conference

NPC2017-Su05 - Controversies & Challenges in Modern Pain Management

Aug 20, 2017 11:00am ‐ Aug 20, 2017 1:15pm

Credits: None available.



11:00 Medical Cannabis & Opioids: Tim Furnish, MD

11:45 The Complexities of Opioid Titration & Opioid Use Disorder: Angella Barr, MD

12:30 Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use: Mark Schumacher, MD, PhD


  • Jensen, B., Chen, J., Furnish, T., & Wallace, M. (2015). Medical marijuana and chronic pain: a review of basic science and clinical evidence. Current Pain and Headache Reports, 19(10), 50.
    Abstract: Cannabinoid compounds include phytocannabinoids, endocannabinoids, and synthetics. The two primary phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), with CB1 receptors in the brain and peripheral tissue and CB2 receptors in the immune and hematopoietic systems. The route of delivery of cannabis is important as the bioavailability and metabolism are very different for smoking versus oral/sublingual routes. Gold standard clinical trials are limited; however, some studies have thus far shown evidence to support the use of cannabinoids for some cancer, neuropathic, spasticity, acute pain, and chronic pain conditions
  • National Academies of Sciences, Engineering, and Medicine. 2017. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press. https://doi.org/10.17226/24781.


  • Dr. Tim Furnish, MD, Associate Clinical Professor of Anesthesiology and Pain Medicine, UC San Diego
  • Dr. Angella Barr, MD, Medical Director, Chemical Dependency and Treatment Associates Inc.
  • Dr. Mark Schumacher, MD, PhD, Chief, Division of Pain Medicine, UCSF Department of Anesthesia and Perioperative Care
Category: CME


Credits: None available.

You must be logged in and own this session in order to post comments.